HER2 levels may aid in treatment selection for metastatic breast cancer

Findings published in the December 1, 2008, issue of Clinical Cancer Research, a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit. In addition, a misclassification of metastatic breast cancer patients by as much as 10 percent prevents some people from receiving optimal therapy.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news147443771.html">HER2 levels may aid in treatment selection for metastatic breast cancer</a></p> <p>Findings published in the December 1, 2008, issue of <I>Clinical Cancer Research</I>, a journal of the American Association for Cancer Research, show lapatinib benefits women with HER2-positive breast cancer, while women with HER2-negative breast cancer or those who express EGRF alone derive no incremental benefit. In addition, a misclassification of metastatic breast cancer patients by as much as 10 percent prevents some people from receiving optimal therapy.</p>